Testing Restarts
Lives Safely
The world has changed. People’s livelihoods and the health of the world may never be “as it was” pre-pandemic.
In these times we all need peace of mind: NanoParma™ provides rapid, easy-to-use, and accurate testing for COVID-19 screening and immune protection.
Let’s go travel, enjoy a meal, attend a game, and work safely again!
NanoParma™ Testing enables individuals to safely and conveniently self-test for COVID-19 immune protection.
Test at a workplace, an event, at home or anywhere! Results can be uploaded to ParmaPass™
where maps of COVID-19 “safe zones” can be found for any community you reside in or need to travel to. Let’s work together to create better health for everyone!
See how NanoParma™ can help restart lives safely.
Testing
Empowers
Communities
Choose A Scenario:
WHY
SeraParma™
TESTING
RAPID
Fast and reliable results in only 20 minutes
Early detection and early intervention
EASY-TO-USE
Free from the fear of nasal and throat swabs
Results from Saliva/finger stick blood tests
ACCURATE
Over 99% of sensitivity and specificity
As accurate as the “Gold Standard" PCR testing
immune protection
Testing for SARS-CoV-2 neutralizing antibodies
The level of immunity against COVID-19
WHY
SeraParma™
TESTING
RAPID
Fast and reliable results in only 20 minutes
Early detection and early intervention
EASY-TO-USE
Free from the fear of nasal and throat swabs Results from either Saliva or Blood test
ACCURATE
Greater than 99% sensitivity and specificity
As accurate as “Gold Standard" PCR testing
immune protection
Testing for SARS-CoV-2 neutralizing antibodies
Tests for COVID-19 immunity
WHY
SeraParma™
TESTING
RAPID
Fast and reliable results in only 20 minutes
Early detection and early intervention
EASY-TO-USE
Free from the fear of nasal and throat swabs
Results from Saliva/finger stick blood tests
ACCURATE
Over 99% of sensitivity and specificity
As accurate as the PCR testing
immune protection
Testing for SARS-CoV-2 neutralizing antibodies
The level of immunity against COVID-19
NanoParma™ testing is an easy-to-use, rapid and accurate COVID-19 antibody testing system.
MucoParma™ tests saliva for IgA (infection) while SeraParma™ tests for IgM, IgG and neutralizing antibodies (immunity) using only a single drop of blood.
Types of
NanoParma™
Testing
MucoParma™ COVID-19 IgA
IgA is a primary class of antibodies found in saliva, part of the mucosal membrane system. When someone is infected with SARS-CoV-2, IgA initially rises as early as IgM. By testing saliva IgA, MucoParma™ enables organizations and individuals to rapidly screen for infection with ease and convenience.
SeraParma™ COVID-19 IgM
IgM is a major class of antibodies produced by the immune system and circulated in the blood once someone is infected with SARS-CoV-2 virus. A positive IgM test indicates the body is currently infected and means the immune system is responding to COVID-19.
Usually, a lateral flow based rapid antibody test is not used for infection diagnoses due to its lack of sensitivity. However, SeraParma™ possesses 1,000 times higher sensitivity than conventional lateral flow technologies. The secret is in the nanoparticle. Data has shown 100% agreement between FDA validated results for PCR testing and those of SeraParma™ testing for COVID-19 IgM. Furthermore, by testing IgM, we get to know the precise status of a patient’s infection and/or immunity and are able to take the right action to help make communities safer.
SeraParma™ COVID-19 Neutralizing Antibodies
After recovery from COVID-19, IgG may remain in one’s blood circulation but it’s not guaranteed those antibodies are able to defend SARS-CoV-2 in the future. Similarly, after receiving a vaccine shot, it’s not guaranteed the antibodies produced by one’s immune system can defend future COVID-19. It takes specific neutralizing antibodies to defend cells from SARS-CoV-2 infection. Our testing of SeraParma™ COVID-19 Neutralizing Antibodies is to confirm the existence of the neutralizing antibodies that possess immune protection from COVID-19.
MucoParma™ COVID-19 IgA
IgA is a primary class of antibodies found in saliva, part of the mucosal membrane system. When someone is infected with SARS-CoV-2, IgA initially rises as early as IgM. By testing saliva IgA, MucoParma™ enables organizations and individuals to rapidly screen for infection with ease and convenience.
SeraParma™ COVID-19 IgM
IgM is a major class of antibodies produced by the immune system and circulated in the blood once someone is infected with SARS-CoV-2 virus. A positive IgM test indicates the body is currently infected and means the immune system is responding to COVID-19.
Usually, a lateral flow based rapid antibody test is not used for infection diagnoses due to its lack of sensitivity. However, SeraParma™ possesses 1,000 times higher sensitivity than conventional lateral flow technologies. The secret is in the nanoparticle.
Data has shown 100% agreement between FDA validated results for PCR testing and those of SeraParma™ testing for COVID-19 IgM. Furthermore, by testing IgM, we get to know the precise status of a patient’s infection and/or immunity and are able to take the right action to help make communities safer.
SeraParma™ COVID-19 Neutralizing Antibodies
After recovery from COVID-19, IgG may remain in one’s blood circulation but it’s not guaranteed those antibodies are able to defend SARS-CoV-2 in the future.
Similarly, after receiving a vaccine shot, it’s not guaranteed the antibodies produced by one’s immune system can defend against future infections.
SeraParma™ tests for specific SARS-CoV-2 Neutralizing Antibodies to confirm the existence of immune protection from COVID-19.
ParmaPass™
Safe Zones
We all want the pandemic to be over. We all hope to get back to normal. But history has taught us that vaccination alone cannot single-handedly control a virus.
To avoid lockdown cycles experienced in 2020, we need to curb the spread of the virus using a three-pronged strategy: 1.Vaccinations, 2.Testing/Isolations, and
3.Safe Zone mapping strategies.
NanoParma™ provides innovative testing tools, and also a safe-zone mapping tool to complement the on-going vaccination efforts throughout the world.
Our open-source ParmaPass™ app generates time-stamped, blockchain verifiable certificates of immune status for anyone who has been tested and shared his/her testing results anonymously. Safety is on the way!
Our Team
Jesse Chih-Wei Lin
CEO
MT(ASCPi), MBA
BS in Medical Technology, National Taiwan University (NTU)
Co-founder of BioInnovation Taiwan
President of NTU MedTech Alumni Association
7+ years experience in MedTech startup business consulting
Young Taiwan Scholar for Global Health Forum in Taiwan (2017)
Howard Hong-wei yang
CTO
Professor at the Institute of Medical Science & Technology, National Sun-Yat-Sen University (NSYSU), Taiwan
Distinguished Young Scholar in NSYSU (2019-2022)
NIH Postdoctoral Fellow, Georgia Institute of Technology, USA (2013-
2014)
Outstanding Paper Award, Association of Chemical Sensors in Taiwan
(2017/2019/2020)
Project for Excellent Junior Research Investigators, Ministry of
Science and Technology (2017~2021)
erik wainwright
CMO
15+ years experience in cross culture communication
7+ years experience as executive life coach and marketing consulting
Co-founder of ASHERS LEAVEN
Founding member of BioInnovation Taiwan
Studied Sociology/ Social Psychology/ Cultural Anthropology at Washington State University
Marketing Group
Miya Wu
Anita Hsu
EJ Wu
R&D Group
Lancelot Lee
Hans pang
Emily hsu
MucoParma™ SARS-COV-2 IgA
IgA is the primary class of antibodies found in saliva, part of mucosal membrane system. When one is SARS-CoV-2 infected, IgA rises as early as IgM (ref). By testing saliva IgA, MucoParma™ enables individuals and business to screen infection rapidly.
SeraParma™ SARS-COV-2 IgM/IgG
IgM is the major class of antibodies produced by immune system and found in blood circulation when one is SARS-CoV-2 infected. A positive IgM test indicates a current COVID-19 and the immune system is responding it.
IgG is produced in COVID-19 patients within 7-10 days after infection. IgG usually remains in the blood after one recovers from the infection to protect one from future infection.
Usually, a lateral flow based rapid antibody test is not used for infection diagnosis due to its compromised sensitivity. However, SeraParma™ possesses 1,000 times higher sensitivity than the old lateral flow technology. Data showed 100% agreement between results of FDA validated PCR tests and SeraParma™ COVID-19 IgM/IgG. Furthermore, by testing IgM and IgG simultaneously, we get to know the status of one’s infection and take the right action.
